2024, Fragment Screening and Treatment

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2024

Fragment Screening

Treatment

Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1

Covalent Modifiers

MARCH 19, 2024

Flaherty Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.3c01661 Thus, UCHL1 inhibitors could serve as a viable treatment strategy against these aggressive cancers. Herein, we describe a covalent fragment screen that identified the chloroacetohydrazide scaffold as a covalent UCHL1 inhibitor. Muli, Aaron D.

Fragment Screening

Fragment Screening Disease Treatment

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

APRIL 7, 2025

This receptor is also expressed in the brain, where it helps to regulate dopamine release, making it a therapeutic target for the treatment of insomnia, pain, depression and Parkinson’s disease. Available at: [link] (Accessed: 23 September 2024). References Sun D, et al. Jones EM, et al. doi:10.7554/elife.54895.

Fragment Screening

Fragment Screening Drugs Biophysical Assays Small Molecule

Drug Discovery Digest

Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1

Advancements in hit identification for membrane protein drug discovery

Stay Connected